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Abstract
Background: Clinically significant levels of fear of cancer recurrence (FCR) affect up to 49 % of cancer survivors and
are more prevalent among women. FCR is associated with psychological distress, lower quality of life, and increased
use of medical resources. Despite its prevalence, FCR is poorly addressed in clinical care. To address this problem,
we first developed, and pilot tested a 6-week, 2 h, Cognitive-existential group intervention therapy that targeted
FCR in survivors of breast or gynecological cancer. Following the positive outcome of the pilot, we are now testing
this approach in a randomized clinical trial (RCT).
Goal and hypotheses: This multicenter, prospective RCT aims to test the efficacy of the intervention. The study
hypotheses are that, compared to a control group, cancer survivors participating in the intervention (1) will have
less FCR, (2) will show more favorable outcomes on the following measures: cancer-specific distress, quality of life,
illness uncertainty, intolerance of uncertainty, perceived risk of cancer recurrence, and coping skills. We further
postulate that the between-group differences will persist three and 6 months post-intervention.
Methods: Sixteen groups of seven to nine women are being allocated to the intervention or the control group.
The control group receives a 6-week, 2 h, structurally equivalent support group. We are recruiting 144 cancer
survivors from four hospital sites in three Canadian cities. The sample size was based on the moderate pre/post-test
changes found in our pilot study and adjusted to the drop-out rates. Measurements: The primary outcome, FCR, is
measured by the Fear of Cancer Recurrence Inventory. Secondary outcomes measured include cancer-specific
distress, perceived risk of cancer recurrence, illness uncertainty, intolerance of uncertainty, coping, and quality of life.
We use reliable and recognized valid scales. Participants are to complete the questionnaire package at four times:
before the first group session (baseline), immediately after the sixth session, and 3 and 6 months post-intervention.
Analysis: In the descriptive analysis, comparison of group equivalent baseline variables, identification of
confounding/intermediate variables and univariate analysis are planned. Each participant’s trajectory is calculated
using Generalized Estimating Equation models to determine the time and group effects, after considering the
correlation structures of the groups. An intent-to-treat analysis approach may be adopted.
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Discussion: Our Fear of Recurrence Therapy (FORT) intervention has direct implications for clinical service
development to improve the quality of life for patients with breast (BC) and gynecological cancer (GC). Based on our
pilot data, we are confident that the FORT intervention can guide the development of effective psychosocial cancer
survivorship interventions to reduce FCR and improve psychological functioning among women with BC or GC.
Trial registration: Dr. Christine Maheu registered the trial with ISRCTN registry (Registration number: ISRCTN83539618,
date assigned 03/09/2014).
Keywords: Fear of cancer recurrence, Randomized clinical trial, Cognitive-existential group therapy, BREAST cancer,
Gynecological cancer, Coping, Quality of life, Cancer distress
Background
According to the 2015 Canadian Cancer Statistics, approxi-
mately 42 % of all women will be affected by cancer in their
lifetime [1]. Although most cancer patients complete treat-
ment and survive, survivors continue to struggle with fear
of cancer recurrence [FCR]. FCR often describes a fear or a
worry that cancer will return or progress in the same organ
or into another part of the body [2, 3]. FCR is the most
common problem reported by cancer survivors [3, 4], with
reports ranging from 49 % in prostate cancer survivors to
74 % in lung cancer survivors [5]. A study involving a large
cohort of long-term breast cancer survivors (n = 2671)
found that fear of recurrence was highly prevalent (82 %)
[6]. Despite the overrepresentation of women in this sample
and that, gender’s association with FCR is still inconclusive
although higher mean scores have been observed in women
[7], the high prevalence rate underscores the need to ad-
dress this concern in clinical practice.
While providing clinical care to such large group of can-
cer survivors may prove difficult, placing priority on indi-
viduals experiencing higher levels of FCR may be more
feasible. From the literature, there is still no consensus on
what constitutes low, moderate, and high levels of FCR.
However, some current practice has been to classify low,
moderate, and high based on the mean value of the total
FCR scores used ± 1 SD [8]. In instances where a clinical
cut-off of FCR has been established within a scale [9], this
score tends to represent moderate to high levels. From the
reported 2671 cohort reported in Koch et al. study [6], the
majority had low levels of FCR with 17 % experiencing
moderate to high levels. Compared to percentages found
in systematic reviews, this percentage is relatively low. Sys-
tematic reviews of quantitative studies report prevalence
rates of 49 to 66 % for moderate-to-high levels of FCR in
cancer survivors [3, 8].
In a less recent cross-sectional study involving 1721
patients with mixed cancer sites and tumor stages, fear
of disease progression or recurrence was found to be the
most important single distress with 32.2 % of them rat-
ing this concern has strongly to very strongly distressed
[5]. Their population was very heterogeneous, yet
interesting determinants for psychological distress to
prioritize for service delivery include patients with
gynecological cancers within 6 months after diagnosis
and cancer types with much longer treatment duration
tending towards the 5-years survival rate criteria. Other sys-
tematic reviews demonstrate that high FCR measured at
the end of treatment is a strong predictor of high long-
term FCR [3, 8, 10, 11]. Overall, there is a trend for FCR to
remain stable over the course of post cancer treatment [8].
Moderate-to-high levels of FCR are consistently asso-
ciated with psychological distress, anxiety, depression,
and stress-response symptoms (with correlations ranging
from r = .19 to .69), suggesting relationships among
these constructs, but not a strong overlap [3]. High
levels of FCR are also associated with diminished phys-
ical and mental quality of life (QoL) [12–16], including
increased uncertainty and worry about the future, diffi-
culties making decisions about the future, and fear of
death [13]. Cancer patients with high levels of FCR are
more likely to refuse transfer from a specialized cancer
center and to be followed-up care by a primary care pro-
vider [17]. They are less satisfied with their care [18], ex-
press doubt about whether their physicians are thorough
enough [18], and are more likely to seek readmission to
a cancer center [17]. Need for reassurance is often cited
as the reason for increased frequency of hospital visits
[19]. As such, cancer survivors with moderate-to-high
levels of FCR tend to have maladaptive coping reactions,
such as hypervigilance, excessive body checking and ex-
cessive need for reassurance seeking [20–23].
Despite clear evidence that cancer patients who exhibit
moderate-to-high FCR have higher rates of psychological
distress and may incur additional medical costs [24], few
psychosocial interventions have been empirically tested to
reduce FCR [3, 10, 11, 25]. This gap leaves clinicians ill-
equipped to guide their patients with empirically tested in-
terventions on how to reduce and cope with FCR. This
gap prompted us to conduct a pilot study using a
Cognitive-existential group approach. The results of our
pilot study have been published [26, 27]. We are now test-
ing the Cognitive-existential group While this approach is
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further being testing in a clinical trial named the Fear of
Recurrence Therapy [FORT] intervention.
Previous counseling approaches to fear of cancer
recurrence
While there are several ongoing trials of FCR interven-
tions [28–30], to date only one published intervention
trial has addressed fear of disease progression, a concept
related to FCR, in people with cancer or chronic arthritis
[31]. This intervention involved both a cognitive behav-
ioral group and a supportive-expressive group, and it
successfully decreased fear of disease progression com-
pared to a control group. However, all cancer partici-
pants were inpatients admitted to a rehabilitation clinic,
and 20 % of them had recurrence or metastases. Hence,
the concept of fear of disease progression addressed in
this intervention may be more applicable to in-patients
with active or advanced disease than to out-patients and
those in remissions or with early-stage disease. Another
intervention has been developed to address FCR among
head-and-neck-cancer patients [32], but results of this
trial have not yet been published.
Four additional studies evaluated group therapies de-
signed to improve general psychological wellbeing out-
comes for breast cancer survivors and reported on FCR as
a secondary outcome. The first study evaluated the impact
of a 6-session Mindfulness-Based Stress Reduction (MBSR)
group and found a significant decrease in FCR immediately
following the six sessions [33]. However, no follow-up study
was conducted to evaluate the long-term effectiveness of
the intervention, and the study did not include an attention
only control group. The second study reported similar find-
ings from an 8-session MBSR group [34] but, again, the
study did not include an attention only control group, and
the sample was small. The third study reported significant
reductions in FCR immediately following a 12-week Emo-
tion Regulation Group [35]. However, improvements in
FCR were not sustained at 6 and 12 months after the inter-
vention. Fourth, a telephone intervention designed to im-
prove communication between breast cancer survivors and
their physicians did not decrease FCR (the secondary out-
come), although the intervention did improve the primary
outcome, self-efficacy [36].
As described above, to date no intervention studies
have reported an effective means of reducing FCR when
it is the primary outcome for out-patient, disease-free
survivors, with long-term impact and when the study in-
cludes an attention only control group. These gaps
prompted us to develop the FORT intervention, a
cognitive-existential (CE) group intervention that specif-
ically targets FCR as its primary outcome and includes a
structurally equivalent control group with post-
intervention measurement at 6 months.
Rationale for the cognitive-existential therapy interven-
tion for fear of cancer recurrence
Cognitive-behavioural therapy (CBT) tends to be brief
and structured, with a focus on skills in monitoring and
modifying (in this case cancer-related and underlying
fears) thoughts, emotions, and behaviors (e.g., building
coping skills, relaxation training, goal setting, problem-
solving) [37–39]. Most important for cancer survivors,
CBT for health conditions now recognizes the import-
ance of existential issues such as fear of the future and
fear of death [37, 38]. Given the existential aspect associ-
ated with FCR, we decided to take a therapeutic ap-
proach that not only emphasized education, cognitive
reappraisal, enhanced coping but also focused on exist-
entially oriented strategies. Since many patients may not
readily let go of their maladaptive coping reactions un-
less they can be helped to accept the ‘unspoken’ part of
their experience (their fear of cancer recurrence), it was
assessed that CBT alone would not likely help them.
To address patients’ fear, we chose the Cognitive-
Existential (CE) approach elaborated by Kissane et al.
[40, 41] to guide the development of FORT intervention,
along with Lee-Jones et al.’s conceptual FCR model [42].
Themes in the CE approach relevant to our intervention
include death anxiety, FCR, living with uncertainty, and
future goals [41]. We also designed a group approach,
rather than individual because group interventions are
as efficacious in reducing distress among cancer patients
as individual therapy [43, 44]. Group interventions offer
several other advantages as well over individual therapy.
In addition to cost-effectiveness, they allow participants to
recognize their shared struggle and existential pain, to con-
nect and learn from one another, and to feel understood
and valued as they support one another [26]. In our pilot
study of the group intervention, the women expressed ap-
preciation in hearing other women’s strategies for dealing
with FCR and shared inputs on how to improve the inter-
vention [26]. The shared experiences facilitated group cohe-
sion, making discussing sensitive topics, such as fear of
treatment and death, more comfortable.
Rationale for offering the intervention to breast and
gynecological cancer survivors
The target populations for our RCT are breast and
gynecological cancer (BC and GC) survivors. Although
these two populations have different prognoses, they both
have a high prevalence of moderate-to-high FCR [45, 46].
Furthermore, systematic reviews have found few if any dif-
ferences in FCR scores by cancer type [3, 10, 25]. While
testing interventions with more than one cancer type po-
tentially increase the number of confounding factors to
control for, it also increases the external validity of
the intervention. Our RCT comprises the same two
target populations as our pilot study. In the pilot
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study, analysis by cancer type revealed no group dif-
ference in the efficacy of the FORT intervention. We,
therefore, expect that the two types of cancer survi-
vors will respond similarly to the FORT intervention
in the RCT. However, group assignments to the inter-
vention are by cancer type.
Aims of RCT
The aim of this RCT is to test the effectiveness of a
cognitive-existential (CE) group intervention, the FORT
intervention, in reducing fear of cancer recurrence
among breast (BC) or gynecological (GC) cancer
survivors.
Research question and hypotheses
The research questions are as follow:
What is the effectiveness of the FORT intervention
(2 h group sessions for 6 weeks), compared with a struc-
turally equivalent control group, in reducing FCR in the
short term (immediately after the end of the intervention
at T2) and in the long term, at 3 months (T3) and
6 months (T4) after the intervention?
The main hypotheses are as follow:
1. Compared to a structurally equivalent control
group, BC and GC survivors participating in the
FORT intervention will (a) have less FCR and (b)
show greater improvement in the following
secondary outcomes: cancer-specific distress, coping
skills, illness uncertainty, quality of life, intolerance
of uncertainty, and perceived risk of cancer
recurrence.
2. Group differences will be maintained over the
6 months following the intervention, at T3
(3 months post-intervention) and T4 (6 months
post-intervention).
Methods/design
We are conducting this RCT with four specialized can-
cer centers in two Canadian provinces. The study is
funded by the Canadian Cancer Society and is registered
with the ISRCTN under Dr. Maheu (Clinical Trial No.
ISRCTN83539618, date assigned 03/09/2014). Ethical
approval has been obtained from all four participating
centers. All possible precautions were taken to safeguard
the rights and privacy of the participants.
Participant selection
Patients are eligible to participate if they:
 Have a confirmed past diagnosis of breast (BC) or
gynecological cancer (GC), in stages 0–3;
 Are disease-free at the start of the group;
 Are 18 years or older;
 Have completed treatment, except for targeted
therapy or hormonal therapy;
 Have a score of 13 or greater on the severity
subscale of the Fear of Cancer Recurrence Inventory
(range 0–36), suggesting clinical levels of fear of
cancer recurrence (FCR) [9];
 Have a score of at least 24 on the cancer-specific
distress measure of the Impact of Events Scale
(range 0–75), indicating clinical levels of distress
[47, 48].
 Can read and write English; and
 Can give informed consent.
If participants develop a recurrence in the course of
the study, they remain in the group intervention, but
their follow-up data are not used in the study.
Patients are ineligible to participate if they:
 Had a previous cancer recurrence;
 Are enrolled in another psychotherapy group at the
start of the study or during their six sessions;
 Have an unresolved mental health disorder based on
disclosure by the potential participant that may
affect the group’s work as assessed by the group
leader at the pre-interview session.
Participant recruitment
We are recruiting 144 BC or GC survivors from four
hospital sites: Princess Margaret Hospital and Mount
Sinai Hospital in Toronto, Ontario, the Ottawa Hospital
in Ottawa, Ontario, and the Jewish General Hospital in
Montreal, Quebec. Both the Toronto and Ottawa sites
see approximately 300 BC and 250 GC patients a year.
The Toronto sites are providing 4 to 5 iterations of the
FORT intervention; the Ottawa site is providing 3; and
the Montreal site one. Because of the higher number of
BC patients than GC patients served by these centers,
75 % of the groups will comprise BC patients. Each
group (the FORT and the structurally equivalent group
control) comprises 6 to 8 women, but up to 9 women
per group are being recruited to accommodate possible
drop-outs.
Each recruiting site has placed recruiting posters in its
waiting area, as well as beside key elevators that patients
use on follow-up visits. We also work with the sites’
medical staff to inform eligible participants about the
study and seek their consent to be contacted by a re-
search assistant (RA). When the RA contacts potential
participants, she explains the study and screens them for
eligibility. Study pamphlets with tear-off forms in which
potential participants can give their contact information
are also placed in the waiting areas of BC and GC
follow-up clinics. A locked drop box is left at each
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participating sites waiting areas for potential participants
to insert their contact information.
Following confirmation of eligibility, patients are
scheduled to meet with one of the group leaders for a
pre-interview assessment. The goal is to review group-
work expectations and to assess whether group work fits
with patients’ expectations. If both parties agree that
group work is a good match, study information is
reviewed, written consent is obtained, and a copy of the
baseline assessment questionnaire is given to the patient,
along with a stamped, pre-addressed envelope. Potential
participants are advised to mail in their baseline assess-
ment questionnaires before the start of the first group
session.
Randomization of participants
Before randomization, all of the following forms are
completed by all eligible and consenting participants: (a)
eligibility form, (b) consent form, (c) baseline measures,
and (d) baseline interview form. Randomization of all
recruiting sites is centralized at one recruiting site and is
performed by a biostatistician working at arm’s length
from the study. The biostatistician does not know the
identity of the therapists and gives the group allocations
to the study’s RA. The group allocation is concealed to
the participants. The participants do not know which
groups comprise the FORT intervention or the structur-
ally equivalent control group. Randomization occurs
each time 18 BC survivors or 18 GC survivors are
deemed eligible at one of the four sites. This ratio of 18
ensures nine women in each group, with a buffer of at
least two probable dropouts per group. We achieved this
target in our pilot study. Each group is planned to start
within 2 weeks of the initial randomization of women to
each study arm.
The fear of recurrence therapy intervention
The FORT intervention is theoretically guided by the
FCRM [26, 27], Leventhal’s Common Sense Model [42, 49],
Mishel’s Uncertainty in Illness Theory [50], and cognitive
model of worry [51].
Perceived risk of recurrence
According to Leventhal’s Common Sense Model, FCR is
best viewed as a multidimensional construct in which in-
ternal and external cues increase perceived risk of recur-
rence, which in turn heightens FCR [15, 42, 52]. Examples
of internal triggers include aches and pains. External trig-
gers include anniversary dates of cancer diagnosis, attend-
ing cancer screening appointments, and hearing of a
friend with a recurrence. There is evidence that perceived
risk may be the link between triggers and FCR, as sug-
gested by Leventhal’s Common Sense Model [42]. Per-
ceived risk of recurrence tends to lead survivors to focus
on sensations that, before their cancer diagnosis, would
have been viewed as normal or, at least, benign (e.g., occa-
sional pain) and to now interpret these as evidence of re-
currence. To influence levels of perceived risk, in the
intervention, participants are taught to identify internal
and external triggers and their link with FCR.
Coping strategies
Once patients perceive a risk of recurrence, there is in-
creased the likelihood of maladaptive coping and behav-
ior such as anxious preoccupation, excessive body
checking, and reassurance seeking, including from
health practitioners [32]. Strong empirical evidence sup-
ports the reciprocal relationship between coping and
FCR. Patients with moderate-to-high FCR become pre-
occupied and report excessive body checking [53], re-
assurance seeking [3], and avoidance coping such as
pushing away intrusive thoughts of possible recurrence
[54, 55]. While such coping strategies provide temporary
relief at best, they tend to increase FCR over time by
feeding hyper-vigilance and reinforcing maladaptive cop-
ing behaviors [19, 32, 42]. Our FORT intervention fo-
cuses on identifying maladaptive coping behaviors and
their consequences and then replacing these with more
favorable coping skills.
Uncertainty
According to Uncertainty in Illness Theory [50], uncer-
tainty is generated when components of an illness pos-
sess the characteristics of inconsistency, randomness,
complexity, unpredictability, and lack of information in
situations of importance to the individual [56]. Living
with constant uncertainty increases psychological dis-
tress and perceived risk, and reduces the quality of life
[50, 56]. To reduce uncertainty about living with cancer,
participants learn about the signs that indicate actual
cancer recurrence vs. benign symptoms.
Intolerance of uncertainty and faulty beliefs about the
benefits of worrying
Cognitive models of worry suggest that worriers have a
lower tolerance for uncertainty than non-worriers [51].
Patients with elevated FCR may consider inadequate
anything less than the complete certainty that they are
cancer-free, which may explain their increased use of
coping strategies, such as seeking medical reassurance
or body checking. While uncertainty indicates ambiguity
associated with cancer and its treatment, intolerance of
uncertainty reflects a difficulty in tolerating and coping
with even small amounts of ambiguity or uncertainty in
facing cancer. Cognitive models of worry also suggest
that worriers tend to believe that worrying is beneficial.
By worrying, they think they can prevent negative out-
comes. In our FORT intervention, participants are
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taught to challenge their beliefs in the benefits of worry
and to develop new coping skills to tolerate better
uncertainty.
Content and processes of the intervention
Two leaders facilitate each group (for both the interven-
tion and control groups). Table 1 gives the content of
the FORT group sessions. Group leaders cannot add
new participants once a six-session group has started.
This procedure is necessary to enhance group cohesive-
ness and consistency [57]. At their pre-study-interview
sessions, participants are told that, if they are absent for
more than one group session, they will be asked to with-
draw from the study, because too much material and group
process development will have been missed. However, the
participants are told that, if they have to be absent for only
Table 1 Content of the Fear of Recurrence Therapy (FORT) intervention sessions
Session number Description
1. - Self-introduction by each participant, with a focus on their experience with fear of cancer recurrence.
- Introduce major heading of the Fear of Recurrence Therapy (FORT) from the six sessions.
- Introduce the automatic thought, behavior, and consequence therapy model and the fear of cancer recurrence model (FCRM).
- Introduce notions of cognitive restructuring and how to identify FCR triggers.
- Teach and practice progressive muscle relaxation.
Homework: Practice progressive muscle relaxation daily. Complete thought journal and challenge maladaptive thinking
about the fear of cancer recurrence.
2. - Prepare questions for nurse specialist, who provides education about general cancer screening guidelines and signs
of recurrence in Session 3.
- Help participants deal with the fact that uncertainty can never be eliminated.
- Discuss ways of regaining a sense of control using Wheel of Life exercise.
- Teach calming self-talk. Provide participants with relaxation CD audio and instruct them to use calming self-talk phrases
with their relaxation CD when appropriate.
Homework: Listen to CD every day. Practice calming self-talk. Complete thought journal and challenge maladaptive
thinking about the fear of cancer recurrence. Prepare questions for the specialist nurse visit in Session 3.
3. - Visit from nurse specialist.
- Increase tolerance for uncertainty by discussing acceptable levels of worry.
- Challenge faulty beliefs about benefits of worry.
- Decrease maladaptive coping strategies.
- Teach and practice guided imagery.
Homework: Practice guided imagery daily. Continue challenging faulty beliefs about benefits of worry. Complete thought
journal, adding a column for behaviors to monitor coping strategies that participants are adopting.
4. - Provide psycho-education about worry and the need for exposure to worst fears.
- Promote emotion expression and confront specific fears that underlie fear of cancer recurrence.
- Write down worst-fear scenario.
- Teach and practice mindfulness using a body scan through breathing exercise.
Homework: Read worst-fear scenario every day and then do a self-care activity. Practice mindfulness exercises daily.
5. - Review exposure to worst fear scenario exercise.
- Discuss ways of coping with some of the feared outcomes.
- Promote expression of demoralization feelings.
- Encourage participants to re-engage with important life goals, people or activities they may have given up.
- Discuss what meanings the future and planning now have for them.
- Teach and practice mindfulness using eating meditation (Raisin meditation).
Homework: Challenge their worst fear scenarios into more likely realistic ones. Write down goals and priorities for the future.
6. - Review all content covered.
- Discuss future goals.
- Set new priorities.
- Promote saying good-bye to the group and provide closure.
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one session, one of their group leaders will contact them to
review the session’s content and the homework to be done
before the next session. When participants miss more than
one session, they are withdrawn from the group and then
invited to join a group that has not yet started. Traveling
expenses of both the FORT intervention and the control
groups are reimbursed. Both groups are provided with re-
freshments 30 min before the start of each weekly session
to allow group members to settle in and chitchat. This
strategy increases group cohesion and facilitates starting
the group on time.
At the first session, participants in the FORT interven-
tion receive a binder describing the intervention’s frame-
work as well as each session’s activities. At the beginning
of the first session, group leaders review the key goals of
the intervention. The key goals of the FORT intervention
are to:
1. Distinguish worrisome symptoms from benign ones.
2. Identify FCR triggers and inappropriate coping
strategies.
3. Facilitate the learning and use of new coping
strategies, such as relaxation techniques and
cognitive restructuring.
4. Increase tolerance for uncertainty.
5. Promote emotional expression of specific fears that
underlie fear of cancer recurrence.
6. Reexamine life priorities and set realistic goals for
the future.
The participants are shown the in-group activities and
the short assignments to complete at home. The latter
reinforce concepts learned during the group sessions
and help participants prepare for the next session’s con-
tent. At the end of each session, take-home homework’s
for the following week is reviewed and, at the beginning
of the next session, participants’ homework’s is reviewed.
As part of their study package, participants receive a CD
or audio file containing six different relaxation tech-
niques (deep breathing, progressive muscular relaxation,
guided imagery, body scanning, deep relaxation, and en-
couraging sleep). Each of these techniques is discussed
or practiced in one of the group sessions.
Content of the control group intervention
Participants assigned to the control group receive a
structurally equivalent intervention to rule out the possi-
bility that attention received from FORT-group facilita-
tors and the social support received during the FORT-
group sessions, rather than the FORT intervention itself,
is responsible for the FORT intervention’s effectiveness.
To this end, the control group sessions have a structure
similar to the FORT but different content. Specifically,
the control group receives six, weekly, 2 h sessions,
delivered by two health care professionals. Although the
sessions focus on the challenges of living with a cancer
diagnosis, the six sessions comprise a general support
group but do not include the unique ingredients of the
FORT intervention. Nonetheless, the intervention and
control groups possess common factors in equal meas-
ure such as length and number of sessions, and both led
by two health professionals [58]. During the control
group sessions, the following topics are discussed: (a) ex-
ploring what it means when you find out you have can-
cer, (b) coping with post-treatment symptoms and side
effects, (c) challenges of living with a cancer diagnosis,
(d) incorporating wellness into your daily life, (e) build-
ing a survivorship plan, and (f ) managing transitions
(from active treatment to resuming work and family life).
While the group leaders are instructed to create a sup-
portive atmosphere in which patients may share their
worries about living with a cancer diagnosis, the thera-
pists are instructed not to teach the linkages between
emotions and behaviors. Specifically, in the control
group, potential therapeutic ingredients found in the
FORT intervention group, such as cognitive reframing,
building coping skills, or exposure to participants’ worst
fears are not introduced. Group leaders in the control
group are instructed to use reflection and restatement
when participants do introduce these topics DL Safer
and EM Hugo [58]. Although the control group com-
prises specific weekly topics, the content, and flow of
each session are not highly scripted, no homework is
assigned, and no relaxation exercises are taught during
the sessions or practiced at home. The group leaders are
expected to have clinical experience with cancer patients
and general knowledge about the weekly topics.
Standardization and training in the FORT intervention and
control intervention
To set performance standards and ensure treatment fi-
delity [59–61], we developed a FORT intervention man-
ual and tested it in the pilot study for dosage (number of
sessions) and intensity (duration of each session). After
this pre-testing, the manual was refined for the RCT. All
FORT facilitators receive the same 2-day training, under
the direction of the first, second, third, and fourth au-
thors, all of whom are well trained in Cognitive existen-
tial therapy. FORT leaders also attend annual, 1-day
training refreshers to maintain their competency and to
avoid therapist drift-off (e.g., expanding the session con-
tent based on insights from their clinical experience).
We used this approach to monitoring treatment integrity
and fidelity successfully in our pilot study.
Two specific control group leaders, with previous ex-
perience in delivering support groups to women with
cancer, were asked by the research team to develop a
manual for group leaders and participants, based on six
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established topics for the control group. The two
control-group leaders did not participate in the FORT
intervention training, to reduce risk of content contam-
ination, and they provided training to group leaders at
the other intervention sites. Analogous quality-control
fidelity checks for reliability and consistency are done on
both intervention and control groups.
All group sessions are audio-recorded and reviewed,
with participants’ permission. The audio-recording are
accessible only to the research team. The first and sec-
ond authors independently and randomly review 20 % of
all recordings, using fidelity checklists built from each of
the intervention manuals. The checklists have two rat-
ings: (a) areas covered (yes or no) and (b) quantity and
quality of area covered (0–2). The second rating assesses
adherence to the manuals, adequate processing of affect
in the FORT intervention, and efficient time manage-
ment. When adherence to the manuals is less than 80 %,
the first and second authors review with group leaders
how to improve adherence.
Pilot study of the intervention
The pilot study of the FORT intervention was carried
out between October 2010 and October 2012, with fund-
ing from the Canadian Institutes of Health Research [26,
27]. The pilot study assessed the feasibility and prelimin-
ary efficacy of the FORT intervention for 56 participants
with either BC or GC. Briefly, we found that the inter-
vention was feasible and showed promising efficacy. Spe-
cifically, women who took part in the intervention
reported significant reductions in the primary outcome,
FCR, and the secondary outcomes uncertainty, coping,
cancer-specific distress, and quality of life, as measured
before and immediately after the intervention. These
changes were maintained 3 months after the interven-
tion ended. Our RCT builds on the findings of the pilot
study by comparing the FORT intervention to a struc-
turally equivalent control group. In planning the RCT,
we carefully took into account the issues found in the
pilot study. First, although most psychological measures
showed improved outcomes, we observed changes on
only four of the 14 coping subscales, This result may
suggest that the coping scale we chose for the pilot study
may not have been specific enough to measure changes
in other coping behaviours such as for cognitive avoid-
ance, reassurance seeking, body checking that we had
aimed to reduce, as based on our theoretical FCRM [27].
For the RCT, we, therefore, revised our coping measures
to align them more closely with our theoretical model.
Second, in the pilot study, we used an FCR measure that
did not have a validated cut-off score for identifying clin-
ically significant levels of FCR. Recent developments in
psychometrics have made it possible to distinguish survi-
vors with minimal FCR from those with clinical levels of
FCR [11]. Consequently, for the RCT, we changed our
measurement of FCR scale to a more reliable scale, the
Fear of Cancer Recurrence Inventory, which has a vali-
dated clinical cut-off score based one of its subscales,
the FCR severity scale [9]. The scale also provides a total
FCR score [9]. We also reorganized the content of the
weekly sessions, based on participants’ feedback [26].
One example was moving the nurse specialist’s presenta-
tion on cancer screening follow-ups from Session 2 to
Session 3, to allow participants to learn coping skills for
confronting anxiety associated with hearing about cancer
risk. Finally, in the pilot study whereas therapeutic gains
were not assessed beyond 3 months, the RCT includes a
6-month follow-up measurement.
Primary and secondary outcomes in the RCT
The theoretical model for our pilot study guided the
choice of measures included in the RCT questionnaire
package. There are four measurement time-points for
participants randomized to either the intervention or the
control group: 2 weeks before the intervention (T1)
1 week after the intervention (T2), and 3 and 6 months
after the intervention ends (T3 and T4, respectively).
The first questionnaire package (T1) includes additional
measures to evaluate the intervention and control
groups’ comparability, such as demographic data includ-
ing age and socioeconomic status, and medical history
of cancer diagnosis.
The primary outcome of the study, fear of cancer re-
currence, is measured by the Fear of Cancer Recurrence
Inventory (FCRI) [9]. This 42-item questionnaire in-
cludes a total score as well as seven subscales, measuring
triggers, FCR severity, psychological distress, functional
impairment, insight, reassurance, and coping strategies.
A score of 13 or higher on the nine-item severity sub-
scale (range 0–3) indicates a clinical level of FCR [62].
The FCRI has been shown to have adequate reliability
and validity (construct validity r = 0.68 to 0.77; reliability
scores α = 0.95) [9].
The secondary outcomes are measured as follows:
Cancer-specific distress is measured by the Impact of
Event Scale (IES) [47], a 15-item questionnaire that as-
sesses cancer distress. The IES has two subscales: intru-
sive thoughts and avoidance. The scale has good internal
consistency (α = 0.84–0.91) and satisfactory test-retest
reliability (total r = 0.80) [63]. Perceived risk of cancer re-
currence is measured by a single-item question asking
respondents to indicate their level of perceived personal
risk for cancer recurrence over the last two days [64]. In-
tolerance of uncertainty is measured by the Intolerance
of Uncertainty Scale (IUS) [65]. The IUS is a 27-item,
four-factor questionnaire that presents uncertainty as
stressful and upsetting, uncertainty as leading to the in-
ability to act, uncertain events as being negative and to
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be avoided, and being uncertain as unfair [65]. The IUS
has a reliability coefficient of r = 0.74 [65]. Uncertainty
in Illness is measured by the Mishel Uncertainty in Ill-
ness Scale–Community version [56], which consists of
23 items rated on a five-point Likert scale. For cancer,
this scale has alpha coefficients of 0.90 [66]. Coping is
measured by the following three coping scales: (a) Cogni-
tive Avoidance Questionnaire [67], a measure of avoid-
ance coping of 25 items, (b) the Reassurance-Seeking
Behaviours subscale of the Health Anxiety Questionnaire
[68], a measure of body-checking and seeking reassur-
ance of 3 items, and (c) the Reassurance Question-
naire [69], a measure of seeking reassurance from
physicians of 10 items These coping measures have
been extensively used for cancer patients as well as
with other patients who have health anxiety. The mea-
sures have demonstrated satisfactory reliability and valid-
ity [56, 67, 70, 71]. The quality of life is measured by the
SF-8 instrument [72], a health-related quality of life meas-
ure that assesses general physical and mental health within
a 4-week recall period. Cronbach’s alpha internal
consistency for both subscales is 0.61-0.68 [73].
Potential covariates
As group cohesion may influence the intervention’s im-
pact, we measure group cohesion at the end of each 6-
week FORT-intervention group and each 6-week control
group intervention. Cohesion is measured using the
Group Cohesion Scale − Revised [74], a 25-item scale
measuring interaction and communication among group
members. For example, one item is “Group members
usually feel free to share information.” The Cronbach’s
alpha internal consistency of this scale ranged from .77
to .90 during post-test assessment [74].
Group alliance within therapy groups can be thera-
peutic in and of itself and can enhance intervention effi-
cacy [75]. That is, patients who perceive improvements
during their therapy are more likely to have positive feel-
ings towards the therapist, be more committed to treat-
ment, and work more collaboratively. We measure
group alliance using the California Psychotherapy Alli-
ance Scale [76], a 24-item scale with four theoretically
derived dimensions: (a) the therapeutic alliance, (b) the
working alliance, (c) the therapist’s contribution to the
alliance, and (d) the agreement on goals and tasks of
therapy. We measure therapeutic-working-group alliance
immediately following the last sessions of both the inter-
vention and the control groups.
Treatment credibility and participants’ expectancy for
improvement are two additional variables that may con-
tribute to alternative explanations of differences found
between two compared conditions [77]. To assess cred-
ibility and expectancy to ensure initial equivalency be-
tween the FORT intervention and the structurally
equivalent control group, we are using the Credibility/
Expectancy Questionnaire (CEQ) [77]. The CEQ has 6
items; three items relate to the credibility factor (“think”
questions), and three items relate to the expectancy fac-
tor (“feel” questions). Each factor demonstrates high in-
ternal consistency (α = 0.81 for expectancy and α = 0.86
for credibility) and a good Cronbach’s alpha for the
whole scale (α = 0.85) [77]. Test-retest reliability over a
1-week period scored at 0.82 for expectancy and 0.75 for
credibility [77]. The CEQ has two ratings; one is from 1
(not at all) to 9 (very much), and the other from 0 %
(not at all) to 100 % (very much). Scoring involves trans-
forming the percentage to a number between 1 and 9,
giving both scales a range from 3 to 27. The CEQ is
given to participants immediately after the end of Ses-
sion 1, in which the study intervention is explained. Both
the FORT intervention and the control group members
complete this scale.
Sample size
The primary study outcome is FCR, as measured by the
FCRI [9]. The sample size was calculated based on the
moderate changes in FCR we observed in the pilot study
from baseline (T1) to 3 months post intervention [27] and
in the only published RCT intervention study that ad-
dresses the fear of disease progression [78]. A sample size
of at least 112 participants ensures our ability to detect an
effect size of 0.40, with a power of 0.95 and an alpha level
of .05 between pre- and post-intervention FCR measures.
Therefore, we plan to recruit eight groups of seven partici-
pants, for a total of 56 participants per arm. We are also
enrolling an additional two participants per group per
arm, to account for possible dropouts (72 per arm). This
strategy will yield 144 participants in total.
Statistical analysis
Random allocation should help us control for possible
extraneous variations. However, we are also measuring
and controlling for known extraneous variables (if
needed) that could influence our primary outcome. Age,
education, income, and cancer stage have been identified
as possible predictors of FCR [3, 10]. These are being
considered as potential covariates and are measured at
baseline (T1).
Descriptive statistics are being used to present the
study participants’ characteristics. To determine the ef-
fectiveness of our intervention, we are using advanced
regression analysis. Kaplan-Meier curves, period preva-
lence, and cumulative risk models may be used to ex-
plain the time-event analysis. To analyse data from
across the four-time points (T1-T4), we are using Gener-
alized Estimating Equations (GEE) models, with factor-
specific events for each of the outcome variables. Similar
sensitivity analyses are to be used to assess the effect of
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the FORT intervention on the secondary outcomes. All
models will be adjusted for adverse events and other po-
tential confounders. We will also assess treatment bene-
fits for subgroups of participants by analyzing their
sociodemographic, clinical, and psychological character-
istics [79]. To identify key variables that lead to changes
in our outcome variables, we are taking two approaches
to selecting the variables for our regression analyses, in-
cluding intermediate variables. In the first approach, var-
iables will be selected based on background knowledge
and the relationship of the variable to intervention and
outcomes. Our second approach relies primarily on
high-dimensional, automatic variable selection tech-
niques, such as forward and backward selection, and
automatic high-dimensional ‘Proxy’ adjustment [80]. In
our opinion, combining these two approaches yields
more unbiased estimates. For the above analyses, we will
use the statistical software packages IBM SPSS Statistics
22.0 and STATA 14.
Discussion
Clinical significance and contributions
Our Fear of Recurrence Therapy (FORT) intervention
has direct implications for clinical service development
to improve the quality of life for patients with breast and
gynecological cancer. Based on our pilot data, we are
confident that the FORT intervention can guide the de-
velopment of effective psychosocial cancer survivorship
interventions to reduce FCR and improve psychological
functioning among women with BC or GC. Having a
FORT manual developed, psychosocial oncology profes-
sionals can be easily trained to provide FORT to cancer
patients who voice concerns about FCR. The therapy is
also highly adaptable to other non-group formats, such
as individual, in-person, telephone counseling, or tele-
health. Studies are currently underway testing the FORT
intervention in individual [81] and telehealth formats. It
can also be adapted for patients with other cancer types.
Currently, there is a lack of consensus on the defin-
ition, measurement, and theoretical formulation of FCR.
Our RCT findings will contribute to a better understand-
ing of FCR predictors and the cognitive and emotional
interplay involved in the formulation of FCR. Finally, the
RCT will contribute to improving cancer survivorship
programs and development of clinical guidelines for ad-
dressing fear of cancer recurrence.
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